Nonhematologic adverse events
| . | This study (n = 73) . | Kantarjianet al (n = 280)32 . | |
|---|---|---|---|
| All grades, % . | Grade 3, % . | Grade 3/4, % . | |
| Skin rash | 42 | 5 | 8 |
| Bone/muscle/joint pain | 41 | 4 | 2 |
| Headache | 30 | 2 | |
| Dry eye/conjunctivitis | 23 | NR | |
| Fatigue | 22 | 1 | |
| Pruritus | 21 | 4 | 1 |
| Gastric pain | 19 | NR | |
| Nausea/vomiting | 11 | 1 | |
| Fever | 11 | NR | |
| Abdominal pain | 8 | NR | |
| Diarrhea | 7 | 2 | |
| Peripheral edema | 4 | NR | |
| . | This study (n = 73) . | Kantarjianet al (n = 280)32 . | |
|---|---|---|---|
| All grades, % . | Grade 3, % . | Grade 3/4, % . | |
| Skin rash | 42 | 5 | 8 |
| Bone/muscle/joint pain | 41 | 4 | 2 |
| Headache | 30 | 2 | |
| Dry eye/conjunctivitis | 23 | NR | |
| Fatigue | 22 | 1 | |
| Pruritus | 21 | 4 | 1 |
| Gastric pain | 19 | NR | |
| Nausea/vomiting | 11 | 1 | |
| Fever | 11 | NR | |
| Abdominal pain | 8 | NR | |
| Diarrhea | 7 | 2 | |
| Peripheral edema | 4 | NR | |
The frequency of grade 3 nonhematologic AEs in these 73 early CP patients is compared with the data previously reported in 280 IM-resistant or intolerant patients who were treated with nilotinib in late CP.32
NR indicates not reported.